Sanofi India Ltd vs Tyche Industries Ltd Stock Comparison
Sanofi India Ltd vs Tyche Industries Ltd Stock Comparison
Last Updated on: May 04, 2026
Key Highlights
The Latest Trading Price of Sanofi India Ltd is ₹ 3420 as of 04 May 11:02
. The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023
.The P/E Ratio of Tyche Industries Ltd is 0 as of December 2023
. The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023
.The Market Cap of Tyche Industries Ltd is ₹ 0 crore as of December 2023
. The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24
.The Revenue of Tyche Industries Ltd is ₹ 0 crore as of Jun '24
. The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24
.The EBITDA of Tyche Industries Ltd is ₹ 0 crore as of Jun '24
. The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24
.The Net Profit of Tyche Industries Ltd is ₹ 0 crore as of Jun '24
. The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00%
The dividend payout of Tyche Industries Ltd changed from 5.13 % to 24.78 % over 5 quarters. This represents a CAGR of 252.52%
.
About Sanofi India Ltd
Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.
About Tyche Industries Ltd
Tyche Industries Limited was initially incorporated as Siris Soft Limited on July 23, 1998.
The Company changed the name to 'Tyche Industries Limited' with due approval from the RoC in 2004.
TIL is one of the largest manufacturers in India of Glucosamine Hydrochloride and corresponding sodium and potassium salts which are mainly exported to USA and Europe.
Company's operations are predominantly related to the manufacture of bulk drugs intermediates.
The company has established two advanced development centers in the area of e-commerce in New Jersey, USA and Hyderabad.
The company has three business models namely offshore solutions, offsite solutions and onsite solutions.
FAQs for the comparison of Sanofi India Ltd and Tyche Industries Ltd
Which company has a larger market capitalization, Sanofi India Ltd or Tyche Industries Ltd?
Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Tyche Industries Ltd is 125 Cr
What are the key factors driving the stock performance of Sanofi India Ltd and Tyche Industries Ltd?
The stock performance of Sanofi India Ltd and Tyche Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Sanofi India Ltd and Tyche Industries Ltd?
As of May 4, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Tyche Industries Ltd stock price is INR ₹122.92.
How do dividend payouts of Sanofi India Ltd and Tyche Industries Ltd compare?
To compare the dividend payouts of Sanofi India Ltd and Tyche Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.